Pharmafile Logo

Creative Bioarray

Located at Long Island, New York, Creative Bioarray was founded as biomedical company focused on providing comprehensive biotechnology and pharmaceutical array services and products for high-throughput analysis. Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys ‘boots-on-the-ground’ recruitment experts in over 70 countries, addressing individual sites’…

View Profile

Company Details

45-16 Ramsey Road Shirley, New York, NY 11967, United States
+1 631 624 4882

 Latest Content from PMHub 

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...

First impressions matter: Why getting your onboarding right is key for digital engagement

Press Releases | January 20, 2026 | Graphite Digital

As pharma organisations invest extensively in creating engaging content, the onboarding process must not be overlooked. Seamless onboarding is the key to ensuring that HCPs not only meet regulatory standards,...

How can pharma build genuine partnerships with patient communities?

Patient engagement is not optional in pharma – it’s integral. Meaningful partnerships with patients, caregivers and advocates must shape every stage of healthcare and medicines development, driving better outcomes, equity...

How will AI change field training?

White Papers and Resources | January 15, 2026 | Inizio

Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...

The Heart and Mouth Connection Every Woman Needs to Know

For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria Ryan, Chief Clinical Officer at...

Inizio Ignite Sparks a New Era of Connected Advisory Solutions

Press Releases | January 7, 2026 | Inizio

Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what...

Uncovering Inequities in Alzheimer’s Disease Screening and Care

  On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, and treatment. Experts from Komodo Health and Medscape shared findings from their...

Five Predictions That Will Reshape Biopharma Commercialisation in 2026

White Papers and Resources | January 5, 2026 | Nmblr

Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story. It’s a rough patch. A cycle that will reverse. But...